Amarin | AMRN - Gross Profit On Sales


Amarin reported $23.17M in Gross Profit on Sales for its fiscal quarter ending in December of 2025.





Gross Profit On Sales Change Date
AbbVie USD 10.47B 605M Sep/2025
Alnylam Pharmaceuticals USD 829.31M 219.56M Dec/2025
Amarin USD 23.17M 961K Dec/2025
AstraZeneca USD 12.39B 5M Dec/2025
BioCryst Pharmaceuticals USD 153.05M 4.16M Dec/2025
DBV Technologies USD 2.77M 33.21M Sep/2025
Esperion Therapeutics USD 140.59M 94.57M Dec/2025
GlaxoSmithKline GBP 6.18B 106M Dec/2025
Halozyme Therapeutics USD 281.77M 2.41M Sep/2025
Heron Therapeutics USD 29.47M 3.17M Dec/2025
Ionis Pharmaceuticals USD 195M 40M Dec/2025
Nektar Therapeutics USD 21.81M 8.06M Dec/2025
Neurocrine Biosciences USD 787.9M 7M Dec/2025
Novartis USD 10.25B 570M Dec/2025